康莱特在培美曲塞联合顺铂治疗晚期肺腺癌中协同作用王.docVIP

康莱特在培美曲塞联合顺铂治疗晚期肺腺癌中协同作用王 　　[摘要] 目的 探讨康莱特注射液在培美曲塞联合顺铂治疗晚期肺腺癌中的协同作用。 方法 选择2014年3月～2015年7月郑州大学附属肿瘤医院收治的52例晚期肺腺癌患者，按随机数字表法分为观察组和对照组，每组26例。对照组采用培美曲塞与顺铂化疗；观察组采用康莱特注射液联合培美曲塞与顺铂化疗，两组患者接受2周期化疗后比较效果、不良反应及患者生活质量情况。 结果 观察组有效缓解率为41.6%，疾病控制率为54.1%；对照组有效缓解率为32.0%，疾病控制率为48.0%，对照组与观察组疗效方面差异无统计学意义（P 0.05）。与对照组相比，观察组骨髓抑制较轻，两组比较差异有统计学意义（P 0.05）。与对照组相比，观察组生活质量（KPS评分）明显改善，差异有统计学意义（P 0.05）。 结论 康莱特注射液联合培美曲塞与顺铂与培美曲塞与顺铂治疗晚期肺腺癌效果相当，但是加用康莱特注射液骨髓抑制较轻，并且可提高患者的生活质量。 　　[关键词] 康莱特注射液；晚期肺腺癌；培美曲塞；顺铂；生活质量 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1673-7210（2016）01（b）-0138-04 　　[Abstract] Objective To investigate the synergistic effect of Kanglaite Injection combined with Pemetrexed and Cisplatin in the treatment of advanced lung adenocarcinoma. Methods 52 patients with advanced lung adenocarcinoma treated in Tumor Hospital Affiliated to Zhengzhou University from March 2014 to July 2015 were selected. According to random number table method patients were divided into the observation group and control group， each group had 26 cases. Patients in the control group were given Pemetrexed and Cisplatin. Patients in the observation group were given Kanglaite Injection combined with Pemetrexed and Cisplatin. All patients were treated for 2 cycles of chemotherapy. The treatment effect， adverse reaction and patients quality of life between the two groups were compared. Results In the observation group， the effective alleviation rate was 41.6%， the disease control rate was 54.1%； in the control group， the effective alleviation rate was 32.0%， the disease control rate was 48.0%； the treatment effect between the two group had no significant difference （P 0.05）. Compared with the control group， the bone marrow suppression in the observation was slight， with statistically significant difference （P 0.05）. Compared with the control group， the quality of life （KPS score） in the observation improved significantly， with statistically significant difference （P 0.05）. Conclusion Compared with Pemetrexed and Cisplatin， Ka